AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20140462
Drug: Landiolol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.125 mg/kg)
Trial: 18621625
Drug: Topotecan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (2 mg per day or 2.5 mg per day fixed dose for 5 of 7 days for 2 weeks)
Trial: 18621625
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 every 21 days)
Trial: 12445218
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) plus controlled-release chlorhexidine chip (CHX)
Trial: 1752060
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) co-treatment
Trial: 1752060
Drug: Gonadotrophin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin treatment alone
Trial: 6126901
Drug: Melperone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone (50 mg)
Trial: 6126901
Drug: Melperone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone (10 mg)
Trial: 24950987
Drug: Gefitinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (500 mg)
Trial: 17967673
Drug: LCT propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LCT propofol 0.1 mg/kg before induction
Trial: 17967673
Drug: MCT/LCT propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT/LCT propofol 0.1 mg/kg before induction
Trial: 15111341
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 20 mg once-daily for 96 weeks
Trial: 15111341
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 50 mg once-daily for 96 weeks
Trial: 11136277
Drug: Budesonide controlled
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide controlled ileal release (CIR) capsules, 9 mg orally in fasting state
Trial: 11136277
Drug: Budesonide controlled
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide controlled ileal release (CIR) capsules, 9 mg orally after a heavy breakfast
Trial: 9488587
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of oltipraz weekly for 8 weeks
Trial: 9488587
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of oltipraz daily for 8 weeks
Trial: 7541355
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg flurbiprofen patch (n = 65)
Trial: 3170993
Drug: Azelastine 1
RxNorm normalized name: AZELASTINE 137/FLUTIC 50MCG 120D NASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 1 mg twice daily
Trial: 3170993
Drug: Azelastine 2
RxNorm normalized name: azelastine 2.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 2 mg twice daily
Trial: 30124572
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) (16 sessions)
Trial: 28209175
Drug: Strataderm® topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strataderm® topical silicone gel only
Trial: 28209175
Drug: Combined Strataderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Strataderm® topical silicone gel and pressure garment therapy
Trial: 14517705
Drug: Noscapine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noscapine (oral administration)
Trial: 14517705
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no noscapine treatment)
Trial: 11377130
Drug: Ferrous bis-glycinate
RxNorm normalized name: ferrous bis-glycinate HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous bis-glycinate chelate (5 mg of Fe daily per kg for 28 days)
Trial: 11377130
Drug: FeSO4 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeSO4 (5 mg of Fe daily per kg for 28 days)
Trial: 15316606
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg orally, twice daily)
Trial: 9295094
Drug: Migraineurs (Cys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraineurs (Cys or Ser alleles at codon 23 of the 5-HT2C receptor gene)
Trial: 31227537
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (twice a week 1‐hour aerobic and strength exercises supervised by a physiotherapist and twice a week 1‐hour Nordic or power walking)
Trial: 28986667
Drug: PR oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR oxycodone/naloxone
Trial: 28986667
Drug: PR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR oxycodone plus macrogol 3350
Trial: 18384087
Drug: Dietary ecological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary ecological treatments for IBD
Trial: 12826988
Drug: Valerian 400
RxNorm normalized name: valerian 400 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian 400 mg and 800 mg
Trial: 1503379
Drug: Cefotaxime (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (3 g/day intravenously) + Rifaximin (1200 mg/day P.O.)
Trial: 1503379
Drug: Cefotaxime (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (3 g/day intravenously)
Trial: 6423365
Drug: Combined methimazole-lithium
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined methimazole-lithium therapy
Trial: 6423365
Drug: Monotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy of methimazole
Trial: 29381229
Drug: Codrituzumab exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codrituzumab exposure of ≥230 μg ml-1 and high CD16MESF level (>5.26 × 105 MESF at least)
Trial: 22751603
Drug: golimumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab (both doses)
Trial: 9520587
Drug: Information received
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information received through other channels (e.g., weekly magazines)
Trial: 27701901
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about cognitive problems after chemotherapy with reassuring information
Trial: 27701901
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about cognitive problems after chemotherapy without reassuring information
Trial: 27701901
Drug: No information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No information about chemotherapy-related cognitive problems (control group)
Trial: 23572323
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg after each haemodialysis session)
Trial: 23572323
Drug: Pregabalin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75 mg after each haemodialysis session)
Trial: 16942566
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a weekly dose of 200,000 SQ-U
Trial: 16942566
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a weekly dose of 24,000 SQ-U
Trial: 12749277
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ranitidine and ecabet
Trial: 10811145
Drug: Estriol (E3)
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol (E3) treatment (2 mg/day) for 30 weeks
Trial: 8626978
Drug: Total glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glycerin dose (volume x concentration)
Trial: 1445476
Drug: Propionyl-L-carnitine 500
RxNorm normalized name: GLYCINE PROPIONYL-L-CARNITINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine 500 mg orally, 3 times a day for 180 days
Trial: 31094126
Drug: Oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral progesterone (dydrogesterone) 10 mg twice daily
Trial: 31094126
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (cyclogest pessary) 400 mg daily per rectal use
Trial: 25050521
Drug: Infliximab and
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab and etanercept combination therapy
Trial: 20886606
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b (0.5 μg/kg/wk) and GM-CSF (125 mg/m² 3× weekly)
Trial: 20886606
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg/d) alone
Trial: 20886606
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b and GM-CSF
Trial: 15150203
Drug: Pexelizumab (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n = 1553)
Trial: 2685007
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human GH therapy (Norditropin; 2 IU/m2.day)
Trial: 25092775
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) once every 2 weeks for nine cycles
Trial: 25092775
Drug: Standard neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neoadjuvant chemotherapy (paclitaxel followed by ddAC)
Trial: 23114287
Drug: Exogenous creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous creatine phosphate added to cardioplegic solution
Trial: 11153670
Drug: Rifabutin 300-450
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300-450 mg daily
Trial: 11153670
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rifabutin and clarithromycin
Trial: 8365299
Drug: Maximal doses
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal doses of Ipratropium Bromide (80 micrograms)
Trial: 28115474
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine 300 units/mL (Gla‐300)
Trial: 24993934
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg daily (arm A)
Trial: 24993934
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg plus bicalutamide 50 mg daily (arm B)
Trial: 24462367
Drug: Meals supplemented
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meals supplemented with 1.4 g of cocoa extract (645.3 mg of polyphenols)
Trial: 12759107
Drug: Granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2 mg/day
Trial: 12759107
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg/day
Trial: 12759107
Drug: Granisetron 0
RxNorm normalized name: granisetron 0.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 0 mg/day (control)
Trial: 12759107
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups treated with a 21‐mg nicotine patch
Trial: 10585155
Drug: Affinity oxygenator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Affinity oxygenator with 10 ml of 25% albumin added to the pump prime (Albumin group)
Trial: 8952015
Drug: Prophylactic antiepileptic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antiepileptic drugs (AEDs)
Trial: 2009894
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg and Diltiazem 60 mg combination
Trial: 2009894
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg alone
Trial: 2009894
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg alone
Trial: 6355056
Drug: Placebo (polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (polyethylene glycol ointment and modified aqueous cream)
Trial: 27828768
Drug: Natural Curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural Curcumin (100 mg/L)
Trial: 27828768
Drug: Photogem (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photogem (100 mg/L)
Trial: 27828768
Drug: Natural Curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural Curcumin (25 mg/L)
Trial: 27828768
Drug: Photogem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photogem (25 mg/L)
Trial: 23539534
Drug: PH-797804 3
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-797804 3 mg
Trial: 23539534
Drug: PH-797804 6
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-797804 6 mg
Trial: 23539534
Drug: PH-797804 3
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-797804 3 mg and 6 mg
Trial: 19766947
Drug: PSUNC exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSUNC exposure (treatment)
Trial: 12635671
Drug: dorzolamide 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dorzolamide 3 times daily for 4 weeks
Trial: 12635671
Drug: latanoprost once
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: latanoprost once daily for 4 weeks
Trial: 9176828
Drug: Pediasure with
RxNorm normalized name: Pediasure with Fiber Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediasure with approximately 10 g total dietary fiber/l (PSF10)
Trial: 1544291
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bromfenac
Trial: 1544291
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg bromfenac
Trial: 1544291
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg bromfenac
Trial: 1544291
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bromfenac
Trial: 28440343
Drug: Sildenafil (high-dose)
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil (high-dose)
Trial: 22801672
Drug: Escitalopram, 10
RxNorm normalized name: Escitalopram, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, 10 mg/d (n = 90)
Trial: 19862667
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride 3.75 g/day
Trial: 7848349
Drug: Deponit 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deponit 5 (test patch)
Trial: 25141907
Drug: α1‐adrenoceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α1‐adrenoceptor antagonists (tamsulosin)
Trial: 25141907
Drug: uroflowmetry biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: uroflowmetry biofeedback combined with α1‐adrenoceptor antagonists
Trial: 16921684
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide insufflation at 6 L/min through a Jackson Pratt drain into the pericardium during cardiopulmonary bypass
Trial: 12943177
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine acupuncture therapy and ROM exercise)
Trial: 8829883
Drug: Lactobionate-based solutions
RxNorm normalized name: lactobionate
DrugBank: Lactobionic acid (DB16621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobionate-based solutions
Trial: 8829883
Drug: Hypertonic citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic citrate solutions
Trial: 8829883
Drug: Extracellular solutions
RxNorm normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracellular solutions
Trial: 2072494
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 pethidine (group 1)
Trial: 2072494
Drug: 0.7 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg.kg‐1 pethidine (group 2)
Trial: 2072494
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (0.5 mg.kg‐1 and 0.7 mg.kg‐1 pethidine)
Trial: 6418905
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose branched-chain amino acid (BcAA) hyperalimentation (45% BcAA)
Trial: 6418905
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid solution (24.2% BcAA)
Trial: 25041620
Drug: Intralesional recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional recombinant human epidermal growth factor (rhEGF) 75 μg, thrice-per-week for 8 weeks
Trial: 20142693
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) thrice daily and physical therapy (PT) twice daily during hospitalization.
Trial: 20142693
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) twice daily during hospitalization (Control group).
Trial: 18613962
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination therapies (ACT)
Trial: 15792396
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg once daily) alone
Trial: 15792396
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg once daily) and telithromycin (800 mg once daily) given concomitantly
Trial: 15792396
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg once daily) and clarithromycin (500 mg twice daily) given concomitantly
Trial: 14622692
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs long-term
Trial: 10499947
Drug: Prochlorperazine (PCZ)
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (PCZ) 10 mg intravenous
Trial: 10499947
Drug: Nonakathisic intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonakathisic intravenous therapy (saline solution or antibiotics)
Trial: 7049587
Drug: Amiloride/hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride/hydrochlorothiazide combination (2 tablets per day of 5 mg amiloride plus 50 mg hydrochlorothiazide)
Trial: 7049587
Drug: Hydrochlorothiazide alone
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide alone (50 mg hydrochlorothiazide)
Trial: 29464385
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg administered via i.v. 20 minutes before surgery completion)
Trial: 29464385
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 ml administered via i.v. 20 minutes before surgery completion)
Trial: 24673708
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL; 4 mg intravenously every 21-28 days)
Trial: 24673708
Drug: Clodronate (CLO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (CLO; 1600 mg/d orally)
Trial: 14657744
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with original operation and postoperative therapy, bone grafts from dissected spinous processes, grafts placed from three to five levels, orthosis applied for up to 1 month, neck collar recommended for 1 additional month.